Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Clinical trial NCT05954442 · RECRUITING
Trial details
- NCT number
- NCT05954442
- Sponsor
- Fudan University
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-13
- Primary completion
- 2025-08-01
- Enrollment
- 203
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.